Atherosclerosis and Hyperlipidemia Research
Atherosclerosis is a disorder of the arteries characterized by the formation of hard structures called atherosclerotic plaques. It is a prevalent disorder, accounting for one third of all deaths in North America.
Atherosclerosis and Hyperlipidemia Research Products Targets
- PI 3-kinase (22)
- HMG-CoA Reductase (8)
- Matrix Metalloprotease (16)
- LXR-like Receptor (6)
- Elastase (1)
- Cell Adhesion Molecule (21)
- Lipoxygenase (8)
- Leukotriene and Related Receptor (13)
- Others (7)
- Cyclooxygenase (24)
- Angiotensin-Converting Enzyme (8)
- Chemokine CXC Receptor (9)
- Chemokine CC Receptor (13)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Urotensin-II Receptor (8)
- Angiotensin AT2 Receptor (3)
- Angiotensin AT1 Receptor (9)
- Phospholipase (16)
- Prostanoid Receptor (24)
- Cytokine (15)
- Platelet-Activating Factor (PAF) Receptor (5)
Products for Atherosclerosis and Hyperlipidemia Research - Page 11
- Cat.No. Product Name Information/Activity
-
BCC1178
T0901317
T0901317 is a potent and selective agonist for LXR and FXR, with EC50s of 50 nM and 5 μM, respectively[1,2]. T0901317 induces its anti-proliferative and cytotoxic effects via an LXR-independent mechanism. T0901317 significantly suppresses cell proliferation and induces programmed cell death in a dose- and time-dependent manner. T0901317 can protect mice from high fat diet-induced obesity and insulin resistance.
-
BCC4273
LXR-623
LXR-623 is a brain-penetrant partial LXRα and full LXRβ agonist, with IC50s of 24 nM and 179 nM, respectively.
-
BCC2370
ARP 100
ARP-100 is a potent and selective matrix metalloproteinase MMP-2 inhibitor (IC50=12 nM). ARP-100 interacts with S1' pocket of MMP-2 and shows anti-invasive properties in an in vitro model of invasion on matrigel. ARP-100 shows the less inhibitory activity towards MMP-1 (>50 μM), MMP-3 (4.5 μM), MMP-7 (>50 μM), and MMP-9 (0.2 μM).
-
BCC2371
ARP 101
Inhibitor of MMP-2
-
BCC1223
Batimastat (BB-94)
Batimastat is a potent broad spectrum MMP inhibitor with IC50 of 3, 4, 4, 6, and 20 nM for MMP-1, MMP-2, MMP-9, MMP-7 and MMP-3, respectively.
-
BCC2373
CP 471474
210755-45-6
-
BCC2119
GM 6001
Ilomastat (GM6001) is a potent and broad spectrum matrix metalloprotease (MMP) inhibitor, inhibits MMPs (IC50s, 1.5 nM for MMP-1; 1.1 nM for MMP-2; 1.9 nM for MMP-3; 0.5 nM for MMP-9), with a Ki of 0.4 nM for human skin fibroblast collagenase (MMP-1).
-
BCC2118
Marimastat
Marimastat (BB2516) is a broad spectrum and orally bioavailable inhibitor of MMPs, with potent activity against MMP-9 (IC50=3 nM), MMP-1 (IC50=5 nM), MMP-2 (IC50=6 nM), MMP-14 (IC50=9 nM) and MMP-7 (IC50=13 nM), used in the treatment of cancer. Marimastat (BB2516) is an angiogenesis and metastasis inhibitor, which limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.
-
BCC4679
Minocycline HCl
Minocycline hydrochloride is a broad-spectrum tetracycline antibiotic, acting by binding to the bacterial 30S ribosomal subunit and inhibiting protein synthesis.
-
BCC2120
NSC 405020
NSC 405020 is a novel small molecule inhibitor of MT1-MMP that specifically targets PEX domain rather than the catalytic domain of MT1-MMP with IC50 >100 μM and does not inhibit the catalytic activity of MT1-MMP or MMP-2.


